Navigation Links
Global IVIG Market Report 2013 Edition Research at MarketReportsOnline.com
Date:8/17/2013

Dallas, Texas (PRWEB) August 17, 2013

The Intravenous immunoglobulin (IVIG) market is characterized by fast pace developments in the clinical technology and testing methodology. Despite challenges like stringent regulations and high cost of treatment, the global IVIG market is all set to witness high growth in the coming years as a result of growing ageing population, increasing number of patients with bleeding disorder, and rising health expenditure. Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global IVIG plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, and Grifols.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, the report Global IVIG Market Report: 2013 Edition ( http://www.marketreportsonline.com/267094.html ) predicts the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables, and tests.

With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of the escalating incidences of health related issues originating due to changing lifestyle and continuously changing surroundings, blood plasma industry’s growth is augmented, especially in the segment of immunoglobulins. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.

Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobulins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic values. IgG is naturally manufactured by plasma cells in human body. IgG antibody, also known as immunoglobulin-G is a large Y-shaped protein employed by the body’s immune system for neutralizing foreign substances like viruses and bacteria.

Intravenous immunoglobulin (IVIG) is a blood plasma derivative administered intravenously. It comprises of pooled, polyvalent, IgG (immunoglobulin (antibody) G) extracted from the plasma of more than one thousand blood donors. The very blood plasma derivative is deployed mainly in the treatment of autoimmune disorders, immune deficiencies and acute infections. IVIG has been the key factor to drive the growth of plasma products industry. The demand for IVIG has been growing on account of its increased usage in the treatment of primary immunodeficiency as well as newer neurological indications.

Comprehensive Table of Contents and more for the report Global IVIG Market Report: 2013 Edition at http://www.marketreportsonline.com/267094-toc.html .

Explore more reports on the Biotechnology market at http://www.marketreportsonline.com/cat/biotechnology-market-research.html .

About Us:
MarketReportsOnline.com ( http://www.marketreportsonline.com/ ) is an online market research reports library offering 350,000+ syndicated reports by leading market research publishers from around the world. You also get access to company profiles and SWOT analysis reports for organizations in multiple industries. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Feel free to write to us with any specific requirements you may have on your business intelligence needs. Also explore more reports at http://www.sandlerresearch.org/ .

Read the full story at http://www.prweb.com/releases/intravenous-imunoglobulin/ivig-industry-2013-report/prweb11034507.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Scientific Community Condemns Destruction of Golden Rice Research
2. Ironridge Global Partners, LLC Successfully Concludes Equity Financings of ULURU Inc.
3. BCC Research Publishes a New Report on Global Markets for Next Generation Sequencing (NGS)
4. Global H1N1 Vaccines Market to Reach US $273 Million by 2018, According to a New Report by Global Industry Analysts, Inc.
5. ResearchMoz.us: RFID Blood Monitoring Systems (Blood Refrigerators and Freezers) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
6. Global Adhesives and Sealants Market 2012-2016 - Worldwide Industry Growth, Opportunity, Players, Size And Forecast Research Report Available Online
7. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
8. The Global Next Generation Sequencing (NGS) Market is Poised to Reach $2.7 Billion by 2017 Says Latest Report
9. The Global Surgical Equipment Market to Grow At A CAGR Of 6.25 Percent over the Period 2012-2016
10. Global Crop Protection Chemicals Market Till 2016 - Worldwide Research Report, Industry Share, Size, Trends, Analysis, Growth and Forecast 2012-2016: MarketResearchReports
11. Environmental Concerns & Depleting Fossil Fuels Drive the Global Renewable Chemicals Market, According to New Report by Global Industry Analysts, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, ... Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 ... for preclinical and clinical safety programs. “We’ve seen significant demand for, and we ...
(Date:5/18/2016)... 2016 The Biotech industry continues to ... that there are no opportunities ahead. Today, ActiveWallSt.com has on ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ... Corp. (NASDAQ: OPHT ). Sign up now to ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained ...
(Date:5/17/2016)... -- Haselmeier announces the launch by Merck ... EMA, the European Medicines Agency. Originally launched in 2011 ... new pen version includes enhancements to further improve the ... patients during use. Its enhanced design has ... with a larger display window that improves the readability ...
(Date:5/17/2016)... BASEL, Switzerland , May 17, 2016 /PRNewswire/ ... sciences company located in Basel, Switzerland ... an investigational oral inhibitor of P38 mitogen-activated protein ... ) , Strekin will build the ... Pamapimod in indications in which MAP Kinases play ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):